TY - JOUR
T1 - CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico
AU - Lazalde-Ramos, Blanca Patricia
AU - Martínez-Fierro, Margarita De La Luz
AU - Galaviz-Hernández, Carlos
AU - Garza-Veloz, Idalia
AU - Naranjo, María Eugenia G.
AU - Sosa-Macías, Martha
AU - Llerena, Adrián
PY - 2014/2
Y1 - 2014/2
N2 - Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in Mexican Mestizos. Materials & methods: A total of 508 Amerindians were studied. Genotyping of CYP2D6 5 and multiplication alleles was performed by long-range PCR, while CYP2D62,3,4,6,10,17,29,35,41 and copy number were evaluated by real-time PCR. Results: The most frequent alleles were CYP2D62 (0.05-0.28), CYP2D64 (0.003-0.21) and multiplications (0.043-0.107). CYP2D65,6, * 10 and41 were not observed in the majority of Amerindians, and CYP2D63,17,35 and29 were not detected. The poor metabolizer genotype (4/5) was lower (0.2%) in Amerindians than in Mestizos (5%); conversely, the ultrarapid metabolizer genotype was higher (12.6%) in indigenous groups than in Mestizos (7%). Conclusion: Our data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYP2D6 active alleles in indigenous populations that in Mestizos. Original submitted 14 August 2013; Revision submitted 7 October 201.
AB - Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in Mexican Mestizos. Materials & methods: A total of 508 Amerindians were studied. Genotyping of CYP2D6 5 and multiplication alleles was performed by long-range PCR, while CYP2D62,3,4,6,10,17,29,35,41 and copy number were evaluated by real-time PCR. Results: The most frequent alleles were CYP2D62 (0.05-0.28), CYP2D64 (0.003-0.21) and multiplications (0.043-0.107). CYP2D65,6, * 10 and41 were not observed in the majority of Amerindians, and CYP2D63,17,35 and29 were not detected. The poor metabolizer genotype (4/5) was lower (0.2%) in Amerindians than in Mestizos (5%); conversely, the ultrarapid metabolizer genotype was higher (12.6%) in indigenous groups than in Mestizos (7%). Conclusion: Our data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYP2D6 active alleles in indigenous populations that in Mestizos. Original submitted 14 August 2013; Revision submitted 7 October 201.
KW - CYP2D6polymorphism
KW - Mexican indigenous
KW - allele frequency
KW - pharmacogenetics
KW - predicted phenotype
UR - http://www.scopus.com/inward/record.url?scp=84894430339&partnerID=8YFLogxK
U2 - 10.2217/pgs.13.203
DO - 10.2217/pgs.13.203
M3 - Artículo
C2 - 24533713
SN - 1462-2416
VL - 15
SP - 339
EP - 348
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 3
ER -